RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
Concussions at school may affect academic performance
12 September 2022Study of cancer immunotherapy patients reveals markers of treatment response
13 September 2022RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.
